PARP Inhibitors in First-Line Therapy of Ovarian Cancer: Are There Any Doubts?

Elisena Franzese, Anna Diana, Sara Centonze, Sandro Pignata, Ferdinando De Vita, Fortunato Ciardiello, Michele Orditura

Research output: Contribution to journalReview articlepeer-review


The standard of care for newly diagnosed advanced ovarian cancer (NADOC) is represented by surgical debulking followed by systemic platinum–taxanes combination chemotherapy. At the last European Society for Medical Oncology (ESMO) Congress, results from three trials testing three different poly-adenosine-diphosphate-ribose-polymerase (PARP) inhibitors (olaparib, niraparib, veliparib) in first-line therapy of OC have been presented. For the first time, these studies evaluated the efficacy of PARP inhibitors in this setting and the relative predictive biomarkers for patients' selection. The use of a PARP inhibitor is related with prolonged progression free survival (PFS) in the whole population of NADOC, although the magnitude of benefit varies widely among subgroups, highlighting the need to identify specific biological subtypes into clinical practice. In this minireview, we discuss the updated data available from clinical studies in this scenario.

Original languageEnglish
Article number782
JournalFrontiers in Oncology
Publication statusPublished - Jun 12 2020


  • BRCA 1/2 mutation carriers
  • first line
  • homologous recombination
  • ovarian cancer
  • PARP inhibitor (PARPi)

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'PARP Inhibitors in First-Line Therapy of Ovarian Cancer: Are There Any Doubts?'. Together they form a unique fingerprint.

Cite this